Clinical Trials for Mesothelioma Patients—A Study of Decitabine and FR901228: Disease Characteristics

Read about the disease characteristics for a current clinical trial about the use of Decitabine and FR901228 for patients with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.

Disease Characteristics Criteria:
Histologically or cytologically confirmed primary small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), advanced esophageal cancer, or pleural mesothelioma
Cancers of non-thoracic origin with metastases to the lungs or pleura eligible
Unresectable disease
Primary or metastatic disease must be accessible for biopsy by endoscopic or percutaneous fine-needle aspiration techniques
No limited stage SCLC or operable NSCLC
No active intracranial or leptomeningeal metastases
Patients with prior intracranial metastases that have been treated with prior surgery or radiotherapy are eligible provided there is no evidence of active disease and no requirement for anticonvulsant therapy or steroids after treatment

If you or a loved one has been diagnosed with an Asbestos illness like mesothelioma, lung cancer or asbestosis, complete the form on this page to get a FREE and prompt review of your case by a leading Asbestos attorney. Weitz & Luxenberg is a leading mesothelioma law firm with a substantial history of success in asbestos exposure cases.